Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MPI | P34949 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875798 | 0.82 | USP7 (0.43) | USP7KDM4EALDH1A1LMNAGLA | |
| SCHEMBL13050024 | 0.79 | KDM4E (0.69) | KDM4EALDH1A1LMNAGLAGAA | |
| SCHEMBL27122992 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1LMNAGLAGAA | |
| SCHEMBL875672 | 0.77 | PIK3CD (0.47) | USP7KDM4EALDH1A1LMNAGLA | |
| SCHEMBL875685 | 0.76 | KDM4E (0.56) | USP7KDM4EALDH1A1LMNAGLA | |
| SCHEMBL875453 | 0.76 | LMNA (0.44) | KDM4EALDH1A1LMNAGLAGAA | |
| SCHEMBL14391863 | 0.74 | KDM4E (0.50) | KDM4EALDH1A1LMNAGLAGAA | |
| SCHEMBL26476495 | 0.73 | ADORA3 (0.46) | USP7ALDH1A1LMNANR1H3NR1H2 | |
| SCHEMBL2149452 | 0.73 | GLA (0.49) | KDM4EALDH1A1LMNAGLAGAA | |
| SCHEMBL28659586 | 0.69 | KDM4E (0.59) | USP7KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619202-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | Pfizer Inc (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | PFIZER INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012038850-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | KCNQ5, KCNQ1, KCNQ3 | USP7 4875/4885KDM4E 2185/4885ALDH1A1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.